Inhibition of von Willebrand factor-platelet glycoprotein Ib interaction prevents and reverses symptoms of acute acquired thrombotic thrombocytopenic purpura in baboons

Initial experience from a double-blind, placebo-controlled, clinical outcome study of ARC1779 in patients with thrombotic thrombocytopenic purpura

(2011) Spero R. Cataland et al.   AMERICAN JOURNAL OF HEMATOLOGY

Antithrombotic drug candidate ALX-0081 shows superior preclinical efficacy and safety compared with currently marketed antiplatelet drugs

(2011) H. Ulrichts et al.   BLOOD

Investigational drugs in thrombotic thrombocytopenic purpura

(2011) Patrizia Noris et al.   EXPERT OPINION ON INVESTIGATIONAL DRUGS

A dose ranging phase I/II trial of the von Willebrand factor inhibiting aptamer ARC1779 in patients with congenital thrombotic thrombo - cytopenic purpura

(2011) Petra Jilma-Stohlawetz et al.   THROMBOSIS AND HAEMOSTASIS

How I treat patients with thrombotic thrombocytopenic purpura: 2010

(2010) J. N. George   BLOOD

Thrombotic thrombocytopenic purpura directly linked with ADAMTS13 inhibition in the baboon (Papio ursinus)

(2010) H. B. Feys et al.   BLOOD

Inhibition of von Willebrand factor-mediated platelet activation and thrombosis by the anti-von Willebrand factor A1-domain aptamer ARC1779

(2009) J. L. DIENER et al.   JOURNAL OF THROMBOSIS AND HAEMOSTASIS

Restoration of Plasma von Willebrand Factor Deficiency Is Sufficient to Correct Thrombus Formation After Gene Therapy for Severe von Willebrand Disease

(2008) Simon F. De Meyer et al.   ARTERIOSCLEROSIS THROMBOSIS AND VASCULAR BIOLOGY